Multidrug-resistant Acinetobacter baumannii infections : looming threat in the Indian clinical setting
INTRODUCTION: The recent increase in multidrug-resistant strains of A. baumannii has increased the incidences of ventilator-associated pneumoniae, catheter-associated urinary tract infections, and central line-associated blood stream infections, together increasing hospital stay, treatment cost, and mortality. Resistance genes blaOXA and blaNDM are dominant in India. Carbapenem-resistant A. baumannii (CRAB) International clone-2 (IC-2) are rising in India. High dependency on carbapenems and last-resort combination of tigecycline and polymyxins have aggravated outcomes. Despite nursing barriers, ward closure, environmental disinfections etc for detecting and controlling transmission, MDR isolates and CRAB nosocomial outbreaks continue. Treatment cost overruns by AMR adversely affect 80% of Indians without insurance cover.
AREA COVERED: This narrative review will cover epidemiology, resistance pattern, genetic diversity, device-related infection, cost, and mortality due to multidrug-resistant and CRAB in India. A comprehensive literature search in PubMed and Google Scholar using appropriate keywords at different time points yielded relevant articles.
EXPERT OPINION: It is challenging to enforce policies to control MDR A. baumannii in India. Government and hospitals should enforce stringent infection control measures, surveillance, and antimicrobial stewardship to prevent further spread and emergence of more virulent and resistant strains. Knowledge on antibiotic resistance mechanisms can help design novel antibiotics that can evade, resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert review of anti-infective therapy - 20(2022), 5 vom: 08. Mai, Seite 721-732 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chandra, Prashant [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.05.2022 Date Revised 01.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14787210.2022.2016393 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334149622 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334149622 | ||
| 003 | DE-627 | ||
| 005 | 20231225223112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14787210.2022.2016393 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334149622 | ||
| 035 | |a (NLM)34878345 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chandra, Prashant |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multidrug-resistant Acinetobacter baumannii infections |b looming threat in the Indian clinical setting |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2022 | ||
| 500 | |a Date Revised 01.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The recent increase in multidrug-resistant strains of A. baumannii has increased the incidences of ventilator-associated pneumoniae, catheter-associated urinary tract infections, and central line-associated blood stream infections, together increasing hospital stay, treatment cost, and mortality. Resistance genes blaOXA and blaNDM are dominant in India. Carbapenem-resistant A. baumannii (CRAB) International clone-2 (IC-2) are rising in India. High dependency on carbapenems and last-resort combination of tigecycline and polymyxins have aggravated outcomes. Despite nursing barriers, ward closure, environmental disinfections etc for detecting and controlling transmission, MDR isolates and CRAB nosocomial outbreaks continue. Treatment cost overruns by AMR adversely affect 80% of Indians without insurance cover | ||
| 520 | |a AREA COVERED: This narrative review will cover epidemiology, resistance pattern, genetic diversity, device-related infection, cost, and mortality due to multidrug-resistant and CRAB in India. A comprehensive literature search in PubMed and Google Scholar using appropriate keywords at different time points yielded relevant articles | ||
| 520 | |a EXPERT OPINION: It is challenging to enforce policies to control MDR A. baumannii in India. Government and hospitals should enforce stringent infection control measures, surveillance, and antimicrobial stewardship to prevent further spread and emergence of more virulent and resistant strains. Knowledge on antibiotic resistance mechanisms can help design novel antibiotics that can evade, resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a biofilms | |
| 650 | 4 | |a carbapenem-resistantAcinetobacter baumannii | |
| 650 | 4 | |a cost | |
| 650 | 4 | |a device-associated-hospital-acquired infections | |
| 650 | 4 | |a infection surveillance | |
| 650 | 4 | |a molecular characterization | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a multidrug-resistantAcinetobacter baumannii | |
| 650 | 4 | |a β-lactamases | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 700 | 1 | |a V, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a M, Surulivelrajan |e verfasserin |4 aut | |
| 700 | 1 | |a Cs, Shastry |e verfasserin |4 aut | |
| 700 | 1 | |a Mk, Unnikrishnan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anti-infective therapy |d 2003 |g 20(2022), 5 vom: 08. Mai, Seite 721-732 |w (DE-627)NLM151540101 |x 1744-8336 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:5 |g day:08 |g month:05 |g pages:721-732 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14787210.2022.2016393 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 5 |b 08 |c 05 |h 721-732 | ||